145 related articles for article (PubMed ID: 10100145)
1. Tumour response and radiation-induced lung injury in patients with recurrent small cell lung cancer treated with radiotherapy and concomitant interferon-alpha.
Halme M; Hallman M; Ruotsalainen T; Piilonen A; Taskinen E; Pekonen M; Maasilta P; Mattson K
Lung Cancer; 1999 Jan; 23(1):39-52. PubMed ID: 10100145
[TBL] [Abstract][Full Text] [Related]
2. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).
Bradley JD; Scott CB; Paris KJ; Demas WF; Machtay M; Komaki R; Movsas B; Rubin P; Sause WT
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1173-9. PubMed ID: 11955727
[TBL] [Abstract][Full Text] [Related]
3. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
4. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy.
Okamoto Y; Murakami M; Yoden E; Sasaki R; Okuno Y; Nakajima T; Kuroda Y
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):390-6. PubMed ID: 11872284
[TBL] [Abstract][Full Text] [Related]
5. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer.
Nakayama Y; Makino S; Fukuda Y; Min KY; Shimizu A; Ohsawa N
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):459-67. PubMed ID: 8567349
[TBL] [Abstract][Full Text] [Related]
6. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.
Kunitake R; Kuwano K; Yoshida K; Maeyama T; Kawasaki M; Hagimoto N; Hara N
Respiration; 2001; 68(5):488-95. PubMed ID: 11694811
[TBL] [Abstract][Full Text] [Related]
7. Bronchoalveolar lavage fluid findings following radiotherapy for non-small cell lung cancer.
Maasilta P; Hallman M; Taskinen E; Kivisaari L; Mattson K
Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):117-23. PubMed ID: 8387063
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung.
Holsti LR; Mattson K; Niiranen A; Standertskiöld-Nordenstam CG; Stenman S; Sovijärvi A; Cantell K
Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1161-6. PubMed ID: 3038802
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
[TBL] [Abstract][Full Text] [Related]
10. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
Halme M; Maasilta PK; Pyrhönen SO; Mattson KV
Eur J Cancer; 1994; 30A(1):11-5. PubMed ID: 8142151
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer.
Mattson K; Holsti LR; Niiranen A; Kivisaari L; Iivanainen M; Sovijärvi A; Cantell K
J Biol Response Mod; 1985 Feb; 4(1):8-17. PubMed ID: 2984340
[TBL] [Abstract][Full Text] [Related]
12. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.
Ruotsalainen T; Halme M; Isokangas OP; Pyrhönen S; Mäntylä M; Pekonen M; Sarna S; Joensuu H; Mattson K
Anticancer Drugs; 2000 Feb; 11(2):101-8. PubMed ID: 10789592
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Byhardt RW; Vaickus L; Witt PL; Chang AY; McAuliffe T; Wilson JF; Lawton CA; Breitmeyer J; Alger ME; Borden EC
J Interferon Cytokine Res; 1996 Nov; 16(11):891-902. PubMed ID: 8938564
[TBL] [Abstract][Full Text] [Related]
15. Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Amin NP; Miften M; Kavanagh B; Raben D; Camidge DR; Thornton D; Rochford N; Gaspar LE
J Thorac Oncol; 2011 Sep; 6(9):1553-62. PubMed ID: 21642862
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
18. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
[TBL] [Abstract][Full Text] [Related]
19. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
20. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.
Miller KL; Marks LB; Sibley GS; Clough RW; Garst JL; Crawford J; Shafman TD
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):355-9. PubMed ID: 12738309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
